In 2012, Svein Lien, CEO of Biotech Pharmacon (listed on the Oslo Stock Exchange) contacted Percorso Life Sciences (Dynal Biotech referral) to discuss a North American strategy for the company. At the time Biotech was involved in 3 business; wound healing, enzymes as a supplement, and molecular enzymes.
We incorporated the entity in the U.S. in late 2012. In early, 2013 the company asked Mr. DiCamillo to develop and lead the commercial molecular enzyme effort on a global basis. We recruited business development managers in the U.S., Europe, and Japan in 2013, managed to negotiate a new OEM contract with Affymetrix (eventually ThermoFisher), oversaw the development and introduction of 4 molecular biology kits. In 2016, Mr. DiCamillo led the recruitment of Jethro Holter, PhD, the current CEO of ArcticZymes AS, as Mr. Lien was transitioning out of the company.
Between 2017 – 2019 Mr. DiCamillo managed the supplement business that led to an asset sale to Lallemand, divestiture of Biotec BetaGlucans (wound healing business), and a name change to ArcticZymes AS.
To date Mr. DiCamillo has overseen the growth of ArcticZymes from $700,000 in 2012 to greater than $15,000,000 in revenue for the enzyme manufacturer. Dino was able to dedicate 60% of his time to ArcticZymes AS, invest in the company, member of the management team, build the business globally, all of which led to significant growth in revenue and valuation of the company.